Trial · NCT01184443
Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents
NCT01184443, Phase 3, Terminated, Children's Hospital of Eastern Ontario
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents. Trials, record NCT01184443. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01184443
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents
- NCT number
- NCT01184443
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 38 participants, actual
- Lead sponsor
- Children's Hospital of Eastern Ontario
- Conditions
- Eating Disorder
- Interventions
- Olanzapine
- First posted
- 2010-08-19
- Last updated
- 2014-09-04
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Eating Disorder Symptom Severity Scale | 12 weeks | Psychological Primary Outcome: The Eating Disorder Symptom Severity Scale is a clinician-rated measure of eating disorder severity, and behavioural and cognitive eating disorder symptoms. |
| Primary | Rate of weight gain | 12 weeks | Medical Primary Outcome: Rate of weight gain will be measured throughout the trial. |
| Secondary | Children's Depression Inventory | 12 weeks | Psychological measure that assesses cognitive, behavioural, and somatic symptoms of depression. |
| Secondary | Multidimensional Anxiety Scale for Children | 12 weeks | Psychological measure that assesses anxiety. |
| Secondary | Eating Disorder Examination Questionnaire-Adolescent | 12 weeks | Assesses behaviours and attitudes associated with eating disorders in youth 13 years of age and older. |
| Secondary | The Children's Eating Attitudes Test | 12 weeks | Assesses behaviours and attitudes associated with eating disorders in youth between the ages of 8 and 12. |
| Secondary | Child Behavior Checklist | 12 weeks | Evaluates parents' perceptions of their child's mood and anxiety |
| Secondary | Eating Disorder Restlessness Agitation Drug Sleep Scale (for youth and parents) | 12 weeks | Thes questionnaire asks specific questions about restlessness, eating disorder cognitions, sleep, medication, and the patient's desire to recover from the eating disorder, that are not addressed in the other questionnaires. |
| Secondary | Eating Disorder Inventory-3 | 12 weeks | Psychological measure that assess psychological traits and symptoms relevant to the development and maintenance of eating disorders. |
| Secondary | Overall Safety Profile | 12 weeks | An overall assessment of the safety profile of olanzapine will be done. This will include examination of reported adverse events, vital signs, electrocardiograms, urinalysis, and blood chemistry. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30038658 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01184443
GET https://conductscience.org/api/trials/v1/NCT01184443/registered